ClinicalTrials.gg
CompletedNCT00883194Updated Nov 16, 2020

A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers

A Phase 1/2 interventional study of PRF-108 and Placebo in Pain, sponsored by PainReform LTD. Completed at 1 site in Israel. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.

Sponsored by PainReform LTD · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing ropivacaine in Pain — 3 open to participants now, 3 under way, 1 of them phase 3. Ropivacaine · Pain.

Enrollment
64th of 77
15 · median 60
Started
2010
with 3 others
Phase 1/2
2 of 77
none open now
Registered
10th of 77
by date

Among the 77 studies testing ropivacaine in Pain, this one is the 64th largest by enrollment, is one of 4 that started in 2010, is one of 2 in phase 1/2, and was the 10th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 77 studies testing ropivacaine in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 60 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing ropivacaine in Pain, or all of them as a file.
02

Study summary

This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.

Read the detailed description

This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.

The purpose of this study is to investigate the safety (side effects if any occurs) associated with the single administration of PRF-108 or PRF-110 and evaluate their analgesic effect in an experimentally induced pain model compared with ropivacaine Solution 0.5% and Vehicle Gel.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Experimental Pain Model
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects between 18-60 years of age;
  2. Subjects are within ±10% of ideal body weight/height (based on frame size) as given by the Metropolitan Life Insurance Tables;
  3. Subjects are ASA Category I and in normal physical health as judged by physical and laboratory examinations and have a negative urine based screen for drugs of abuse;
  4. Subjects must agree to refrain from ingesting any analgesic medication for 3 days or 5 half-lives of the drug prior to and during the study period and alcohol for 1 day prior to and during the study period;
  5. Subjects can tolerate a 0.5mL injection of saline in the lower back area.
  6. The subject is capable of reading, comprehending, and signing the form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of any significant hepatic, renal, endocrine, cardiac, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorders, including glaucoma, diabetes, emphysema, and chronic bronchitis;
  2. Subjects with a history of any type of cancer;
  3. Subjects with conditions that affect the absorption, metabolism, or passage of drugs out of the body, (e.g., sprue, celiac disease, Crohn's disease, colitis, or liver, kidney, or thyroid conditions);
  4. Subjects with any history of alcohol or substance abuse (including a positive drug screen test);
  5. Subjects that currently have or have a history of hypertension;
  6. Subjects with a known to any local anesthetic drug;
  7. Subjects with a history of benign prostatic hyperplasia or difficulty in urination;
  8. Subjects with a hematocrit level below the normal range on the screening laboratory examination;
  9. Subjects with any abnormal lab result (as judged by the Principal Investigator);
  10. An abnormal at screening including PR>200 ms, QRS>110 ms, \<380 or >400 ms, lead II T wave abnormalities. Non-specific T wave abnormalities in leads other than lead II are permissible if not accompanied by any other morphological abnormalities.
  11. Subjects with any condition or history felt by the Investigator to place the subject at increased risk;
  12. Subjects who have smoked or chewed tobacco-containing substances within 6 months prior to the start of the study;
  13. Subjects judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
  14. Subjects who have used an drug within 30 days prior to entering the study;
  15. Subjects who have donated blood within 3 months prior to the start of the study (including blood donation related to the surgical procedure);
  16. Subjects who have previously participated in the trial;
  17. Subjects who are members of the study site staff directly involved with the study or a relative of the Sponsor or other personnel involved with the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    1

    PRF-108 Gel, 4% ropivacaine

    Drug: PRF-108

  • Placebo comparator
    2

    PRF-108 Gel, Vehicle

    Drug: Placebo

  • Active comparator
    3

    Ropivacaine Solution 0.5%

    Drug: Ropivacaine

  • Experimental
    PRF-110, 4%

    PRF-110, 4% ropivacaine

    Drug: PRF-110

Interventions

  • DrugPRF-108

    Ropivacaine

  • DrugPlacebo

    PRF-108 Placebo

  • Solution

  • Also known as: ropivacaine

06

What researchers measure

Primary outcomes

  1. The duration of analgesia

    Time frame: 3 days

Secondary outcomes

  1. PRF-108 and PRF-110 Safety

    Time frame: 3 days

07

Study locations

1 site
  • Hadassah University Hospital
    Jerusalem, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2009
First posted
Apr 17, 2009
Start
Oct 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Nov 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00883194
Lead sponsor
PainReform LTD
Responsible party
Sponsor
First posted
Apr 17, 2009
Start date
Oct 2010
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Nov 16, 2020

Study contacts

Michael Naveh
study chair · PainReform LTD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion